Publications by authors named "Mabel Bush"
Article Synopsis
- DLL3 is found in over 70% of small cell lung cancers (SCLC), which are aggressive and have few treatment options, leading to poor patient outcomes.
- HPN328 is a new trispecific T cell-activating therapy that targets DLL3, enhances T-cell activation, and prolongs its presence in the body, showing strong tumor-killing abilities in lab and animal studies.
- Initial tests indicate HPN328 is effective and safe, with plans for a clinical trial to further evaluate its effectiveness in patients with DLL3-expressing cancers.*
Biofilm production is a key virulence factor that facilitates bacterial colonization on host surfaces and is regulated by complex pathways, including quorum sensing, that also control pigment production, among others. To limit colonization, epithelial cells, as part of the first line of defense, utilize a variety of antimicrobial peptides (AMPs) including defensins. Pore formation is the best investigated mechanism for the bactericidal activity of AMPs.
View Article and Find Full Text PDFUsing multiparameter flow cytometry human innate lymphoid cell (ILC) subsets can be detected in the circulation, in relatively low frequencies. Despite the low frequency of ILCs in circulation, ex vivo experiments have demonstrated that these ILCs release extremely large per cell quantities of signature ILC cytokines following activation. To determine how activated ILC cytokine production is regulated, ILC subsets were activated in the presence or absence of the immunoregulatory cytokines IL-10 and TGF-β.
View Article and Find Full Text PDF